SciSparc Ltd. (SPRC)
NASDAQ: SPRC · Real-Time Price · USD
0.224
+0.003 (1.31%)
At close: Oct 11, 2024, 4:00 PM
0.220
-0.004 (-1.96%)
After-hours: Oct 11, 2024, 5:30 PM EDT
SciSparc Employees
SciSparc had 3 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
3
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$959,667
Profits / Employee
-$1,707,333
Market Cap
729.91K
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Aditxt | 47 |
| LogicMark | 27 |
| Genprex | 26 |
| Windtree Therapeutics | 20 |
| Seelos Therapeutics | 16 |
| Catheter Precision | 14 |
| PainReform | 7 |
| GRI Bio | 4 |
SPRC News
- 13 days ago - SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment - GlobeNewsWire
- 17 days ago - SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX - GlobeNewsWire
- 20 days ago - SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment - GlobeNewsWire
- 24 days ago - SciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment - GlobeNewsWire
- 26 days ago - SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy - GlobeNewsWire
- 4 weeks ago - SciSparc Advances $1.85 million Loan to AutoMax, Following AutoMax's Direct Import Agreement with Major Chinese Vehicle Manufacturer - GlobeNewsWire
- 5 weeks ago - SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment - GlobeNewsWire
- 6 weeks ago - SciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based Combination - GlobeNewsWire